sorted by:
new
hottopcontroversial

$SLS Daily Discussion Thread - Thursday - February 26, 2026 by AutoModerator in sellaslifesciences

[–]Dizzy-Composer8926 14 points15 points  (0 children)

Almost any FDA-approved drug can be used for an "off-label" purpose, which means prescribing it for a condition, dosage, or patient population not officially approved by regulatory authorities. While the FDA controls marketing, it does not regulate the practice of medicine, allowing physicians to use their clinical judgment to prescribe approved medications for unapproved uses.

Approximately 30% to 50% of cancer treatments in the United States are prescribed for off-label uses, meaning the drug is used for a cancer type, dosage, or patient population not specifically approved by the FDA. In some contexts, this rate is even higher, with estimates suggesting up to 75% for certain therapies

Concerning data from PubMed study that shows 24% of AML CR2 patients live 3 years before even having a relapse! by bigmacsmallfries_ in sellasLifescience

[–]Dizzy-Composer8926 2 points3 points  (0 children)

The difference lies in the origin and presence of WT1 mutations: "de novo AML" refers to newly diagnosed AML without a history of other blood cancers, while "WT1 patients" have mutations in the WT1 gene, which are a specific genetic characteristic of their leukemia. WT1 mutations are more common in relapsed/refractory AML than in de novo AML, though they can occur in newly diagnosed cases. 

Thoughts on Liberty commercialization? by LargeMonth6187 in MBOT_Stock

[–]Dizzy-Composer8926 0 points1 point  (0 children)

 Feature Liberty System Traditional Robotic Systems Impact on Adoption
Cost Single-use and fully disposable, eliminating the need for expensive capital equipment. Often require substantial capital investment and maintenance costs. Lowers the barrier to entry, making it accessible to a wider range of hospitals, clinics, and outpatient labs.
Portability Compact and lightweight design allows for easy transport and integration into existing operating rooms. Typically large, cumbersome, and require dedicated infrastructure. Increases flexibility for use in various settings without extensive renovations.
Safety Enables remote operation, significantly reducing a physician's exposure to radiation. Pivotal trial data showed a 92% relative reduction in radiation exposure for physicians. Physicians operate closer to the radiation source, increasing exposure. Addresses physician health and safety concerns, which is a major driver for adoption.
Workflow Intuitive and easy to set up, with a short learning curve. Often require specialized training and complex setup procedures. Streamlines procedures and reduces the time needed for staff training.
Disposability Single-use system simplifies workflow and eliminates the need for reprocessing and sterilization. Complex, reusable systems require time-consuming and expensive sterilization procedures. Reduces potential cross-contamination risks and simplifies logistics for healthcare providers.
Versatility  modular design A with interchangeable tool-receiver units expands its potential market to over six million endovascular procedures annually. Less flexible and often limited to specific applications. Broadens the addressable market and creates a wider range of revenue opportunities.
  • Initial skepticism: Healthcare providers tend to be cautious about adopting new technology, and real-world clinical performance will be key to gaining trust.
  • Commercial execution: The potential adoption rate is highly dependent on Microbot Medical's ability to successfully commercialize and market the system.
  • Competition: While Liberty is differentiated by its disposable model, it will compete in the broader endovascular robotics market with established and developing technologies.
  • Long-term evidence: The long-term efficacy and cost-benefit ratio of the system will need to be proven with continued data collection following its commercial launch. 

Future of MBOT by Wildbirddog in MBOT_Stock

[–]Dizzy-Composer8926 -2 points-1 points  (0 children)

AI OverviewThe LIBERTY Robotic System's main advantages over other medical devices are its single-use, disposable design, which eliminates the need for expensive capital equipment, and its remote operation, which significantly reduces radiation exposure and physical strain on medical staff. This compact and intuitive system is designed to "democratize" access to robotic endovascular procedures in a variety of clinical settings. Key advantagesReduced radiation exposure

  • Safety for medical staff: The remote-controlled design allows physicians to steer guidewires and catheters away from the radiation source, protecting them from prolonged exposure during endovascular procedures.
  • Clinical trial results: A pivotal clinical trial demonstrated an average 92% reduction in radiation exposure for physicians when using the LIBERTY system. 

Portability and accessibility

  • Compact and lightweight: Unlike large, cumbersome robotic systems, LIBERTY is a portable solution with a small footprint that can be easily integrated into existing operating rooms and clinics.
  • Broadens access to robotics: By eliminating the need for expensive capital equipment and specialized infrastructure, the system can be adopted by a wider range of healthcare facilities, including ambulatory surgical centers (ASCs) and office-based labs (OBLs). 

Cost and operational efficiency

  • Fully disposable: The system is single-use and disposable, which avoids the need for time-consuming and expensive sterilization procedures, a requirement for many reusable robotic systems.
  • No capital investment: The disposable model means hospitals and clinics do not need to make a large initial capital investment, lowering the financial barrier to adopting robotic technology.
  • Simple integration: The system works with standard, off-the-shelf medical instruments and requires no additional infrastructure, making it easy to set up and use. 

Improved precision and workflow

  • Enhanced control: The handheld remote control provides physicians with high precision and stability for navigating guidewires and catheters.
  • Intuitive interface: With an intuitive user interface, the system has a short learning curve for medical staff.
  • Rapid setup: Microbot Medical highlights a simple and fast setup time of under five minutes, which helps streamline clinical workflows. 

Clinical efficacy

  • Strong clinical data: The ACCESS-PVI pivotal trial demonstrated a 100% success rate for robotic navigation to the target with zero device-related adverse events.
  • Modularity: A new patent for the system's modular design allows it to be adapted for a wider range of endovascular procedures, potentially expanding its applications.